PLx Pharma (PLXP) Posts Earnings Results

PLx Pharma (NASDAQ:PLXP) announced its earnings results on Friday. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.39), MarketWatch Earnings reports. PLx Pharma had a negative net margin of 12.57% and a negative return on equity of 169.28%. The firm had revenue of $0.22 million for the quarter.

Shares of NASDAQ:PLXP traded down $0.04 on Friday, reaching $3.85. 1,360 shares of the company’s stock were exchanged, compared to its average volume of 4,015. PLx Pharma has a twelve month low of $3.05 and a twelve month high of $7.60. The firm has a market cap of $32.32 million, a PE ratio of -1.97 and a beta of 1.68. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.93.

Separately, ValuEngine upgraded shares of PLx Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd.

ILLEGAL ACTIVITY WARNING: This article was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at

PLx Pharma Company Profile

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Further Reading: Technical Analysis

Earnings History for PLx Pharma (NASDAQ:PLXP)

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with's FREE daily email newsletter.

Leave a Reply